When Is An Adverse Event Not An Adverse Reaction?
Executive Summary
Misclassifying adverse events and adverse reactions is a major source of error on drug labels, Leander Fontaine, former head of labeling at Wyeth, said.
You may also be interested in...
With New Power, New Problems: FDA Confronts Complications of Safety Labeling Change Authority
Drug safety labeling changes that cover large classes of drugs are one of the biggest headaches FDA faces, given its new authority in this area under the Food and Drug Amendments Act, which established a new section 505(o) of the Food, Drug and Cosmetic Act.
Janssen’s Sirturo Needs Minor Tweaks To Confirmatory Trial, FDA Panel Says
Gathering more data to assuage concerns about possibly lower efficacy in black patients will be key to converting the accelerated approval to full approval for the tuberculosis drug, FDA’s Anti-Infective Drugs Advisory Committee concludes.